Business Wire

HELICAL-FUSION

13.5.2024 16:01:32 CEST | Business Wire | Press release

Share
Helical Fusion and National Institute for Fusion Science Establish 'HF Collaboration Research Group' and Dedicated Experimental Space for Early Commercial Fusion Reactor Deployment

Helical Fusion has entered a partnership agreement with the National Institute for Fusion Science (NIFS) in March 2024. NIFS has established the "HF Collaboration Research Group" with activities starting in April, special experimental research space has been dedicated onsite at NIFS, which already houses the world's largest superconductor and fusion experimental facility, for Helical Fusion.
With its support from NIFS, Helical Fusion will accelerate the realization of the world's first commercial fusion reactor.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507957768/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Co-Founder, CEO of Helical Fusion Takaya Taguchi (left) and Chief of Industry-Academia-Government Coordination Section of NIFS Ryo Yasuhara (right), shake hands at NIFS in Toki-City, Gifu, Japan. (Photo: Business Wire)

[Background]
Against the backdrop of a projected global population increase of ~1.7 billion by 2050* and the corresponding surge in worldwide electricity demand, conventional power generation methods alone are expected to struggle to meet these needs. Fusion power offers a clean and safe alternative, utilizing inexhaustible fuel supplies, such as seawater, and thus holds the promise as a technology capable of fundamentally addressing these global challenges. With Japan's energy self-sufficiency rate at a low of 13.3% and fossil fuel dependency still exceeding 80%**, research and development efforts have been underway to secure future baseload power sources.

NIFS, boasting one of the world's largest fusion experimental facilities, the Large Helical Device (LHD) in Gifu prefecture, Japan, has been at the forefront of research into helical-type fusion reactors since its establishment by the government in 1989, yielding remarkable results on a global scale. Building on NIFS's expertise, Helical Fusion was founded in 2021, leveraging the speed and agility typical of startups to lead the development of the world's first commercial steady fusion reactor.

While individual collaborative research efforts have been ongoing with NIFS, the firm establishment of the "HF Collaboration Research Group" going forward, as well as a dedicated experimental space, marks a significant step toward strengthening cooperation, aimed towards the early social implementation of fusion energy.
Reference: for the press release from the National Institute for Fusion Science, click here)

[Comment from Mr. Takaya TAGUCHI (Co-founder, CEO of Helical Fusion)]
Helical Fusion is a startup born from the wealth of cutting-edge research achievements and expertise accumulated by NIFS over more than 30 years. We have conducted numerous joint research projects with NIFS in areas such as high-temperature superconducting magnets and liquid metal blankets. Given the growing global expectations of the helical-stellarator fusion approach, to operate as a steady-state commercialized reactor, we have further strengthened our collaboration to accelerate development by establishing this department, as well as setting up dedicated experimental research space. This will not only accelerate joint research but also advance progress in our proprietary tech development, particularly in the field of high-temperature superconducting magnets. We express our feelings of appreciation to the NIFS team for their cooperation and strive to meet everyone's expectations by furthering our efforts in research and development, so as to lead development with global competition towards an operation ready, steady-state fusion reactor. Furthermore, we aim to contribute to the creation of industries where Japan's proud technologies, from basic research to high-end manufacturing, can be leveraged.

[Comment from Mr. Ryo Yasuhara (Chief of Industry-Academia-Government Coordination Section, NIFS)]
The National Institute for Fusion Science has established a collaborative research department with Helical Fusion, called the "HF Collaboration Research Group", in order to conduct research and development for the practical implementation of helical-type fusion reactors. This joint research group will mainly contribute the specialized knowledge and resources of Helical Fusion and NIFS to conduct research activities aimed at realizing helical-type fusion reactor. NIFS aims to contribute to the advancement of fusion science and the establishment of a broad foundation for science and technology through research activities at the highest global standards. We hope that the achievements obtained in this research group will be a step towards realizing sustainable energy.

*“World Energy Outlook 2023” International Energy Agency (https://www.iea.org/reports/world-energy-outlook-2023)
**”The white paper on energy usage 2022”, Agency for Natural Resources and Energy (https://www.enecho.meti.go.jp/about/whitepaper/2023/pdf/)

[About Us]
Helical Fusion is a Japanese start-up company aiming at the social implementation of fusion energy with a magnetic confinement fusion reactor.
Various fusion methods have been developed in the world over the past 60 years as a next generation energy source.
In Japan, the helical fusion method, which uses a superconducting helical coil with a double-helical structure similar to DNA to stably confine high-temperature plasma, has been developed and nurtured to a great extent. We are aiming to develop the world's first steady-state fusion reactor by incorporating more advanced technologies into the helical-stellarator type fusion reactor.
Additionally, Helical Fusion's proprietary development efforts, including high-temperature superconducting magnet vital for realizing commercial reactors, have received Japanese SBIR grant funding, further accelerating progress towards commercialization.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240507957768/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye